Quantification of human immunodeficiency virus type 2 (HIV-2) viral load in plasma: Comparison of three commercial assays

IF 4 3区医学 Q2 VIROLOGY

Journal of Clinical Virology Pub Date : 2024-11-12 DOI:10.1016/j.jcv.2024.105745

Iker Falces-Romero , Isabel García-Pérez , Luz Martín-Carbonero , Julio García-Rodríguez , Jesús Mingorance

{"title":"Quantification of human immunodeficiency virus type 2 (HIV-2) viral load in plasma: Comparison of three commercial assays","authors":"Iker Falces-Romero , Isabel García-Pérez , Luz Martín-Carbonero , Julio García-Rodríguez , Jesús Mingorance","doi":"10.1016/j.jcv.2024.105745","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>There are few validated commercially available HIV-2 assays for the measurement of viral load. Our aim was to compare three commercial assays for the quantification of HIV-2 viral load in plasma of patients with HIV-2 infection from our hospital.</div></div><div><h3>Material and methods</h3><div>We conducted a retrospective study at our tertiary-care hospital, analyzing samples from patients with known HIV-2 infection collected between 2022 and 2023. We compared three commercial assays for quantification of the viral load, Biomérieux® NASBA assay, Thermo Fisher® digital PCR (dPCR) assay and Altona® RT-PCR assay.</div></div><div><h3>Results</h3><div>A total of 27 samples from 11 different patients were included in the study. Sixteen out of them were negative across all three assays. One sample had a low viral load (<2 log copies/mL) detected by the three assays. In five samples a low viral load was only detected by the Altona® assay. The remaining five samples, all from the same patient infected by a multidrug-resistant HIV-2, showed detectable viral load up to 2 log copies/mL by the Thermo Fisher® and Altona® assays, but none of these samples were detected by the Biomérieux® assay.</div></div><div><h3>Conclusions</h3><div>The Altona® RT-PCR assay and the ThermoFisher® dPCR assay could be reliable options as commercial assays for the quantification of HIV-2 RNA in plasma. However, the Biomérieux® NASBA assay, despite detecting both HIV-1 and HIV-2, may have limitations for HIV-2 detection in some cases.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"175 ","pages":"Article 105745"},"PeriodicalIF":4.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1386653224001070","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

There are few validated commercially available HIV-2 assays for the measurement of viral load. Our aim was to compare three commercial assays for the quantification of HIV-2 viral load in plasma of patients with HIV-2 infection from our hospital.

Material and methods

We conducted a retrospective study at our tertiary-care hospital, analyzing samples from patients with known HIV-2 infection collected between 2022 and 2023. We compared three commercial assays for quantification of the viral load, Biomérieux® NASBA assay, Thermo Fisher® digital PCR (dPCR) assay and Altona® RT-PCR assay.

Results

A total of 27 samples from 11 different patients were included in the study. Sixteen out of them were negative across all three assays. One sample had a low viral load (<2 log copies/mL) detected by the three assays. In five samples a low viral load was only detected by the Altona® assay. The remaining five samples, all from the same patient infected by a multidrug-resistant HIV-2, showed detectable viral load up to 2 log copies/mL by the Thermo Fisher® and Altona® assays, but none of these samples were detected by the Biomérieux® assay.

Conclusions

The Altona® RT-PCR assay and the ThermoFisher® dPCR assay could be reliable options as commercial assays for the quantification of HIV-2 RNA in plasma. However, the Biomérieux® NASBA assay, despite detecting both HIV-1 and HIV-2, may have limitations for HIV-2 detection in some cases.

查看原文本刊更多论文

血浆中人体免疫缺陷病毒 2 型（HIV-2）病毒载量的定量：三种商业检测方法的比较。

导言：目前市场上几乎没有经过验证的用于检测病毒载量的 HIV-2 检测方法。我们的目的是比较三种用于定量检测本医院 HIV-2 感染者血浆中 HIV-2 病毒载量的商用检测方法：我们在我们的三级医院进行了一项回顾性研究，分析了 2022 年至 2023 年间收集的已知 HIV-2 感染者的样本。我们比较了生物梅里埃® NASBA 检测法、赛默飞世尔® 数字 PCR (dPCR) 检测法和 Altona® RT-PCR 检测法这三种用于量化病毒载量的商业检测法：研究共纳入了来自 11 位不同患者的 27 份样本。其中 16 份样本的三种检测结果均为阴性。其中一份样本的病毒载量较低（结论：Altona® RT-PCR 检测方法的病毒载量较低）：Altona® RT-PCR 检测法和 ThermoFisher® dPCR 检测法是血浆中 HIV-2 RNA 定量的可靠商用检测法。然而，Biomérieux® NASBA 检测试剂盒虽然可以检测 HIV-1 和 HIV-2，但在某些情况下对 HIV-2 的检测可能存在局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Virology 医学-病毒学

CiteScore

22.70

自引率

1.10%

发文量

149

审稿时长

24 days

期刊介绍： The Journal of Clinical Virology, an esteemed international publication, serves as the official journal for both the Pan American Society for Clinical Virology and The European Society for Clinical Virology. Dedicated to advancing the understanding of human virology in clinical settings, the Journal of Clinical Virology focuses on disseminating research papers and reviews pertaining to the clinical aspects of virology. Its scope encompasses articles discussing diagnostic methodologies and virus-induced clinical conditions, with an emphasis on practicality and relevance to clinical practice. The journal publishes on topics that include: • new diagnostic technologies • nucleic acid amplification and serologic testing • targeted and metagenomic next-generation sequencing • emerging pandemic viral threats • respiratory viruses • transplant viruses • chronic viral infections • cancer-associated viruses • gastrointestinal viruses • central nervous system viruses • one health (excludes animal health)